Shortening of interestrous intervals with cabergoline in bitches: a clinical trial

J Am Anim Hosp Assoc. 2004 Mar-Apr;40(2):115-9. doi: 10.5326/0400115.

Abstract

Two consecutive interestrous intervals (n=46) were recorded in 23 bitches of different breeds. At varying times after day 100 from the onset of the second proestrus, cabergoline (5 microg/kg per os q 24 hours) was administered from early (n=11), mid- (n=10), and late (n=2) anestrus until 2 days after the beginning of the following proestrus. Interestrous intervals (IEI) were significantly shorter in the cabergoline-treated time periods when compared to the nontreated IEI (184+/-4.5 days versus 239+/-4.5 days; P<0.01). The mean number of days of cabergoline treatment until the onset of proestrus was 21.4+/-2.9 (least square means and standard error of the mean [LSM+/-SEM]). Mean cabergoline treatment durations beginning in early, mid-, and late anestrus were 27.4+/-3.7, 17.6+/-3.8, and 5+/-3 days (LSM+/-SEM), respectively. A significant correlation was found between the stage of anestrus in which the treatments began and the duration of the treatments required to induce estrus (0.51, P=0.01).

Publication types

  • Clinical Trial

MeSH terms

  • Anestrus / blood
  • Anestrus / drug effects*
  • Anestrus / physiology
  • Animals
  • Breeding
  • Cabergoline
  • Dogs / blood
  • Dogs / physiology*
  • Dopamine Agonists / blood
  • Dopamine Agonists / pharmacology*
  • Ergolines / blood
  • Ergolines / pharmacology*
  • Estrus / blood
  • Estrus / drug effects*
  • Estrus / physiology
  • Female
  • Progesterone / blood
  • Time Factors
  • Vagina / cytology

Substances

  • Dopamine Agonists
  • Ergolines
  • Progesterone
  • Cabergoline